Gingival pain adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2004 to June 2026, FDA received 7,838 adverse event reports that record the MedDRA preferred term Gingival pain. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 445 reports in the 12 months to June 2026 and 416 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,045 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 445 (under 0.1%) record this term. Reports for female patients were 65.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 111 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Gingival pain name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		138
Aclasta		26
Actemra	Interleukin-6 receptor antagonist	63
Actonel	Bisphosphonate	40
Adalimumab	Tumor necrosis factor blocker	143
Advair Diskus 100/50		29
Afinitor	Kinase inhibitor	67
Albendazole		116
Alendronate sodium	Bisphosphonate	31
Aminosalicylic Acid		29
Amlodipine	Calcium channel blocker	84
Amoxicillin	Penicillin-class antibacterial	29
Aredia		99
Asacol		141
Aspirin	Nonsteroidal anti-inflammatory drug	151
Astrazeneca Covid-19 Vaccine		47
Boniva		55
Brinsupri		27
Budesonide	Corticosteroid	162
Cabometyx	Kinase inhibitor	182
Candesartan	Angiotensin 2 receptor blocker	132
Candesartan cilexetil	Angiotensin 2 receptor blocker	36
Chantix	Partial cholinergic nicotinic agonist	72
Cholecalciferol		102
Comirnaty		107
Commit		44
Cortifoam	Corticosteroid	133
Cortisone	Corticosteroid	77
Cosentyx	Interleukin-17A antagonist	57
Covid-19 Vaccine		27
Crestor	HMG-CoA reductase inhibitor	67
Cyclophosphamide	Alkylating drug	25
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	145
Desoximetasone	Corticosteroid	90
Dupixent	Interleukin-4 receptor alpha antagonist	151
Enbrel	Tumor necrosis factor blocker	221
Entyvio	Integrin receptor antagonist	146
Epinephrine	Catecholamine	77
Epinephrine hydrochloride	Catecholamine	68
Ergocalciferol	Provitamin D2 compound	81
Escitalopram	Serotonin reuptake inhibitor	140
Escitalopram oxalate	Serotonin reuptake inhibitor	28
Esomeprazole	Proton pump inhibitor	134
Felodipine	Dihydropyridine calcium channel blocker	148
Forteo	Parathyroid hormone analog	95
Fosamax	Bisphosphonate	129
Furosemide	Loop diuretic	150
Gabapentin	Anti-epileptic agent	182
Herceptin	HER2/neu receptor antagonist	31
Humira		327
Hydrocortisone	Corticosteroid	140
Hydrocortisone acetate	Corticosteroid	58
Ibrance	Kinase inhibitor	143
Ibuprofen	Nonsteroidal anti-inflammatory drug	32
Imbruvica	Kinase inhibitor	40
Incivek		25
Inflectra	Tumor necrosis factor blocker	83
Infliximab	Tumor necrosis factor blocker	179
Inlyta	Kinase inhibitor	30
Jakafi	Janus kinase inhibitor	38
Kadcyla		27
Kisqali	Kinase inhibitor	34
Lenvima	Kinase inhibitor	43
Levothyroxine		71
Levothyroxine sodium	l-Thyroxine	93
Lisdexamfetamine dimesylate	Central nervous system stimulant	94
Lyrica		41
Mebeverine		62
Mesalamine	Aminosalicylate	160
Metformin	Biguanide	158
Methotrexate	Folate analog metabolic inhibitor	86
Methotrexate sodium	Folate analog metabolic inhibitor	39
Nexium	Proton pump inhibitor	29
Nicorette	Cholinergic nicotinic agonist	109
Nicotine polacrilex	Cholinergic nicotinic agonist	60
Omeprazole	Proton pump inhibitor	148
Oxycodone	Opioid agonist	127
Oxycodone hydrochloride	Opioid agonist	49
Para-Aminosalicylic Acid		94
Pegasys	Interferon alpha	69
Perjeta	HER2/neu receptor antagonist	26
Pomalyst	Thalidomide analog	37
Prednisolone	Corticosteroid	28
Prednisone	Corticosteroid	209
Prolia	RANK ligand inhibitor	283
Pulmicort Turbuhaler		32
Ramipril	Angiotensin converting enzyme inhibitor	40
Reclast	Bisphosphonate	28
Remicade	Tumor necrosis factor blocker	83
Revlimid	Thalidomide analog	196
Ribavirin	Nucleoside analog antiviral	58
Rinvoq	Janus kinase inhibitor	25
Rituxan	CD20-directed cytolytic antibody	25
Rituximab	CD20-directed cytolytic antibody	55
Rosuvastatin	HMG-CoA reductase inhibitor	118
Rosuvastatin calcium	HMG-CoA reductase inhibitor	26
Sulfasalazine	Aminosalicylate	147
Sutent	Kinase inhibitor	171
Tiotropium bromide	Anticholinergic	35
Tozinameran		75
Trastuzumab	HER2/neu receptor antagonist	29
Tysabri	Integrin receptor antagonist	43
Vedolizumab	Integrin receptor antagonist	107
Vyvanse	Central nervous system stimulant	69
Warfarin	Vitamin K antagonist	130
Warfarin sodium	Vitamin K antagonist	113
Xeljanz	Janus kinase inhibitor	72
Xeloda	Nucleoside metabolic inhibitor	27
Xgeva	RANK ligand inhibitor	51
Zoledronic acid	Bisphosphonate	37
Zometa		270

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 58 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Gingival pain name, in order of name
Class	Reports with this term
Alkylating drug	30
Aminosalicylate	312
Angiotensin 2 receptor blocker	188
Angiotensin converting enzyme inhibitor	45
Anti-epileptic agent	229
Anticholinergic	68
Aromatase inhibitor	38
Atypical antipsychotic	37
Benzodiazepine	33
Biguanide	164
Bisphosphonate	282
Calcineurin inhibitor immunosuppressant	33
Calcium channel blocker	94
Catecholamine	77
CD20-directed cytolytic antibody	117
Central nervous system stimulant	185
Cholinergic nicotinic agonist	192
Corticosteroid	925
Dihydropyridine calcium channel blocker	159
Endothelin receptor antagonist	36
Factor Xa inhibitor	34
Folate analog metabolic inhibitor	128
GLP-1 receptor agonist	43
HER2/neu receptor antagonist	99
Histamine-1 receptor antagonist	29
HMG-CoA reductase inhibitor	233
Human immunoglobulin G	26
Integrin receptor antagonist	296
Interferon alpha	71
Interleukin-17A antagonist	63
Interleukin-4 receptor alpha antagonist	153
Interleukin-6 receptor antagonist	68
Janus kinase inhibitor	138
Kinase inhibitor	873
l-Thyroxine	102
Loop diuretic	150
Microtubule inhibitor	40
Nonsteroidal anti-inflammatory drug	262
Nucleoside analog antiviral	60
Nucleoside metabolic inhibitor	87
Opioid agonist	214
Parathyroid hormone analog	99
Partial cholinergic nicotinic agonist	78
Penicillin-class antibacterial	29
Platinum-based drug	26
Poly(ADP-Ribose) polymerase inhibitor	38
Programmed death Receptor-1 blocking antibody	60
Prostacycline vasodilator	35
Proton pump inhibitor	368
Provitamin D2 compound	85
RANK ligand inhibitor	343
Selective T cell costimulation modulator	30
Serotonin reuptake inhibitor	205
Sodium-Glucose cotransporter 2 inhibitor	149
Thalidomide analog	248
Tumor necrosis factor blocker	737
Vascular endothelial growth factor inhibitor	49
Vitamin K antagonist	243

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Gingival pain, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Gingival pain
Age	Reports	Share
Under 2	1	under 0.1%
2 to 11	33	0.4%
12 to 17	24	0.3%
18 to 44	871	11.1%
45 to 64	2,129	27.2%
65 to 74	1,272	16.2%
75 and over	866	11%
Age not given	2,642	33.7%

Sex of the patient in the reports that record Gingival pain
Sex	Reports	Share
Female	5,154	65.8%
Male	2,102	26.8%
Unknown or not given	582	7.4%

Age and sex are as the report gives them. 69.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Gingival pain: adverse event reports that record this term. https://reportedreactions.com/reaction/gingival-pain/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Gingival pain mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page